Compare Firy Inc. (FIRY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Merck & Co., Inc. — how do they compare? Firy Inc. trades at $8.36 (market cap $125.48M), while Merck & Co., Inc. trades at $127.82 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 2433× Firy Inc.'s market cap, and Merck & Co., Inc. pays a 2.75% dividend while Firy Inc. pays none. Which is the better fit depends on your goals.
| FIRY | MRK | |
|---|---|---|
Market Cap | $125.48M | $305.29B |
Sector | Consumer Cyclical | Health |
52-Week High | $12.45 | $129.52 |
52-Week Low | $2.28 | $77.60 |
Enterprise Value | $69.16M | $348.71B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $8.39, up 4.35% today, with a bullish technical signal from moving averages and RSI near oversold levels. The company recently rebranded from Skillz Inc. and reported Q1 2026 revenue growth but continues significant losses, with a net income margin of -57.48%. Cash flow remains negative, though operating losses have narrowed from prior years.
Outlook is mixed: technical momentum and revenue stabilization offer potential upside, but persistent losses, negative cash flow, and weak profitability metrics pose substantial risks. Analyst consensus is neutral with 60% hold ratings, reflecting cautious optimism amid ongoing financial challenges.
Merck (MRK) trades at $128.00, up 5.96% on the day. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal robust profitability with a 73.91% gross margin and consistent earnings beats in recent quarters. The company is actively expanding its oncology pipeline through acquisitions, most notably the $6.7 billion tender offer for Terns Pharmaceuticals announced in April 2026.
The outlook is positive, supported by strong analyst consensus (67.57% Buy rating) and a price target implying ~7% upside. Key opportunities include pipeline expansion via M&A and solid cash flow generation. Primary risks involve integration of large acquisitions, patent cliffs for key drugs, and intense competition in the oncology space, which could pressure future growth margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
